MARKET

PHAR

PHAR

Pharming Group N.V.
NASDAQ
13.16
+0.87
+7.08%
After Hours: 13.42 +0.26 +1.98% 19:30 11/09 EST
OPEN
13.00
PREV CLOSE
12.29
HIGH
13.48
LOW
12.77
VOLUME
20.09K
TURNOVER
--
52 WEEK HIGH
21.34
52 WEEK LOW
9.11
MARKET CAP
931.44M
P/E (TTM)
44.78
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PHAR last week (1102-1106)?
Weekly Report · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Intensity Therapeutics, Inc. (INTS), Pharming Group (PHAR)
TipRanks · 3d ago
MHRA Approves Pharming Group N.V.’s Joenja as First Treatment Specifically for Children with APDS in the U.K.
NASDAQ · 3d ago
Pharming’s Joenja Approved for Children With APDS in U.K.
TipRanks · 3d ago
Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets
Benzinga · 4d ago
Weekly Report: what happened at PHAR last week (1026-1030)?
Weekly Report · 11/02 10:16
Pharming Group Price Target Raised to $41.00/Share From $38.00 by Canaccord Genuity
Dow Jones · 10/29 22:15
Pharming Group Is Maintained at Buy by Canaccord Genuity
Dow Jones · 10/29 22:15
More
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Webull offers Pharming Group NV - ADR stock information, including NASDAQ: PHAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHAR stock methods without spending real money on the virtual paper trading platform.